- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- ALEMBIC PHARMA - PANACEA BIOTECH
ALEMBIC PHARMA vs PANACEA BIOTECH - Comparison Results
Current Valuations
| ALEMBIC PHARMA | PANACEA BIOTECH | ALEMBIC PHARMA/ PANACEA BIOTECH |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 25.1 | -17.3 | - | View Chart |
| P/BV | x | 5.1 | 2.0 | 247.2% | View Chart |
| Dividend Yield | % | 0.7 | 0.0 | - |
Financials
 ALEMBIC PHARMA  PANACEA BIOTECH |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ALEMBIC PHARMA Mar-18 |
PANACEA BIOTECH Mar-14 |
ALEMBIC PHARMA/ PANACEA BIOTECH |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 645 | 149 | 433.8% | |
| Low | Rs | 470 | 82 | 570.8% | |
| Sales per share (Unadj.) | Rs | 166.1 | 84.1 | 197.4% | |
| Earnings per share (Unadj.) | Rs | 21.9 | -18.3 | -119.6% | |
| Cash flow per share (Unadj.) | Rs | 27.5 | -6.7 | -410.4% | |
| Dividends per share (Unadj.) | Rs | 4.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.7 | 0 | - | |
| Book value per share (Unadj.) | Rs | 117.8 | 83.7 | 140.7% | |
| Shares outstanding (eoy) | m | 188.52 | 61.25 | 307.8% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 3.4 | 1.4 | 244.5% | |
| Avg P/E ratio | x | 25.5 | -6.3 | -403.5% | |
| P/CF ratio (eoy) | x | 20.3 | -17.2 | -117.6% | |
| Price / Book Value ratio | x | 4.7 | 1.4 | 343.1% | |
| Dividend payout | % | 18.3 | 0 | - | |
| Avg Mkt Cap | Rs m | 105,090 | 7,074 | 1,485.5% | |
| No. of employees | `000 | NA | 2.8 | 0.0% | |
| Total wages/salary | Rs m | 6,228 | 1,449 | 429.8% | |
| Avg. sales/employee | Rs Th | NM | 1,874.1 | - | |
| Avg. wages/employee | Rs Th | NM | 527.0 | - | |
| Avg. net profit/employee | Rs Th | NM | -407.7 | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 31,308 | 5,154 | 607.5% | |
| Other income | Rs m | 70 | 100 | 70.4% | |
| Total revenues | Rs m | 31,378 | 5,254 | 597.3% | |
| Gross profit | Rs m | 6,431 | -766 | -839.2% | |
| Depreciation | Rs m | 1,055 | 711 | 148.3% | |
| Interest | Rs m | 34 | 1,503 | 2.3% | |
| Profit before tax | Rs m | 5,413 | -2,881 | -187.9% | |
| Minority Interest | Rs m | 0 | 11 | 0.0% | |
| Prior Period Items | Rs m | -81 | -6 | 1,419.3% | |
| Extraordinary Inc (Exp) | Rs m | 0 | 1,771 | 0.0% | |
| Tax | Rs m | 1,204 | 17 | 7,163.7% | |
| Profit after tax | Rs m | 4,128 | -1,121 | -368.2% | |
| Gross profit margin | % | 20.5 | -14.9 | -138.1% | |
| Effective tax rate | % | 22.2 | -0.6 | -3,812.4% | |
| Net profit margin | % | 13.2 | -21.8 | -60.6% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 18,247 | 3,810 | 478.9% | |
| Current liabilities | Rs m | 11,235 | 8,365 | 134.3% | |
| Net working cap to sales | % | 22.4 | -88.4 | -25.3% | |
| Current ratio | x | 1.6 | 0.5 | 356.6% | |
| Inventory Days | Days | 86 | 156 | 55.0% | |
| Debtors Days | Days | 61 | 67 | 91.3% | |
| Net fixed assets | Rs m | 20,035 | 14,480 | 138.4% | |
| Share capital | Rs m | 377 | 61 | 615.0% | |
| "Free" reserves | Rs m | 21,824 | 903 | 2,416.6% | |
| Net worth | Rs m | 22,201 | 5,127 | 433.0% | |
| Long term debt | Rs m | 5,000 | 5,832 | 85.7% | |
| Total assets | Rs m | 39,411 | 19,433 | 202.8% | |
| Interest coverage | x | 160.2 | -0.9 | -17,478.9% | |
| Debt to equity ratio | x | 0.2 | 1.1 | 19.8% | |
| Sales to assets ratio | x | 0.8 | 0.3 | 299.6% | |
| Return on assets | % | 10.6 | 2.0 | 537.7% | |
| Return on equity | % | 18.6 | -21.9 | -85.0% | |
| Return on capital | % | 19.7 | 3.6 | 542.5% | |
| Exports to sales | % | 46.4 | 24.5 | 189.3% | |
| Imports to sales | % | 10.5 | 10.2 | 103.1% | |
| Exports (fob) | Rs m | 14,535 | 1,264 | 1,150.1% | |
| Imports (cif) | Rs m | 3,288 | 525 | 626.6% | |
| Fx inflow | Rs m | 14,722 | 1,539 | 956.4% | |
| Fx outflow | Rs m | 7,026 | 942 | 745.8% | |
| Net fx | Rs m | 7,696 | 597 | 1,288.6% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 3,124 | 599 | 521.4% | |
| From Investments | Rs m | -8,844 | -438 | 2,019.6% | |
| From Financial Activity | Rs m | 5,026 | -303 | -1,661.0% | |
| Net Cashflow | Rs m | -693 | -141 | 490.7% | |
Share Holding
| Indian Promoters | % | 74.1 | 74.5 | 99.5% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 2.9 | 0.6 | 483.3% | |
| FIIs | % | 9.1 | 1.3 | 700.0% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 13.9 | 23.6 | 58.9% | |
| Shareholders | 49,328 | 10,259 | 480.8% | ||
| Pledged promoter(s) holding | % | 0.0 | 35.1 | - |
Compare ALEMBIC PHARMA With: ALKEM LABORATORIES STRIDES SHASUN LTD TTK HEALTHCARE TORRENT PHARMA DISHMAN PHARMA
Compare ALEMBIC PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 132 Points Higher; IT and Healthcare Stocks Witness Buying(Closing)
After trading on a volatile note throughout the day, share markets in India witnessed buying interest during the closing hours and ended the day in green.
Related Views on News
ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)
Jul 30, 2018 | Updated on Jul 30, 2018For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
ALEMBIC PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 7.1% (Quarterly Result Update)
Jul 20, 2018 | Updated on Jul 20, 2018For the quarter ended March 2018, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 7.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
More Views on NewsMost Popular
Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)
Oct 5, 2018Find companies with long term durable moats, which are correcting with the current broader market sell-off.
Why You Should Be Excited, Not Sad, About the 30% Small Cap Crash(Profit Hunter)
Oct 4, 2018Smallcaps have corrected over 30% since the beginning of the year. Find out why Richa Agarwal views this as an opportunity rather than a threat.
Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)
Oct 5, 2018Ajit Dayal on the crisis in the market and in the mutual fund industry.
Why Are Investors In Sundaram Small Cap Fund Anxious(Outside View)
Oct 3, 2018A small cap fund that aims to capitalise on emerging businesses and catch them young. However, its failure in keeping volatility under check is making its investors anxious.
Biggest Corrections in the Stock of Infibeam Avenues(Chart Of The Day)
Oct 3, 2018Infibeam plunged over 70% last week. This was the second biggest single-day fall. But Infibeam witnessed such sharp falls earlier.
More|
| |
ALEMBIC PHARMA SHARE PRICE
Oct 15, 2018 (Close)
TRACK ALEMBIC PHARMA
- Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ALEMBIC PHARMA
ALEMBIC PHARMA - NOVARTIS COMPARISON
COMPARE ALEMBIC PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.